Application of quantitative of preferentially expressed antigen of melanoma gene expression in monitoring acute myeloid leukemia and minimal residual disease

VernacularTitle:黑色素瘤特异性抗原基因定量检测在急性髓系白血病及微小残留病监测中的应用
Author: Shufen HU ; Dongmei TAN ; Weicheng XIE ; Ting PANG ; Zhiwei LIU ; Puzhao WU
Publication Type:Journal Article
Keywords: Leukemia,acute,myeloid; Minimal residual disease; Preferentially expressed antigen of melanoma; Real-time quantitative PCR; Monitoring
From: Journal of Leukemia & Lymphoma 2015;24(2):115-117
CountryChina
Language:Chinese
Abstract: Objective To investigate the expression of the preferentially expressed antigen of melanoma (PRAME) gene in acute myeloid leukemia (AML),and to evaluate its applicability in monitoring minimal residual disease (MRD).Methods Bone marrow specimens were collected from 63 cases of de-novo AML,while 34 samples from 11 patients were tracked for 28 months.The level of PRAME mRNA was measured by real time RT-PCR.Results The PRAME gene expressed in 52.4 ％ (33/63) of de-novo patients,and the positive rate was highest in M3 than that in other subtypes of AML.The expression of PRAME became negative after treatment and increased in the following months before morphology relapse.Conclusion The PRAME gene is highly expressed in AML and could be a useful marker to monitor MRD.